Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
50,000
Stocks News & Analysis
stocks
After earnings, is Microsoft a buy, a sell, or fairly valued?
With third-quarter results surpassing even high-end expectations, here’s what we think of Microsoft stock.
stocks
Albemarle earnings: Shares rally on strong profit growth well above consensus estimates
Albemarle should see sequential profit growth in the second quarter and maintain higher profits through the year.
stocks
Ahead of IPOs, AI giants keep making circular deals. Here’s why that’s a risk - Clone
With OpenAI reportedly missing revenue targets, the imbalanced risks of circular deals become clearer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,986.90 | 25.20 | -0.28% |
| CAC 40 | 8,202.08 | 97.34 | -1.17% |
| DAX 40 | 24,663.61 | 255.08 | -1.02% |
| Dow JONES (US) | 49,596.97 | 313.62 | -0.63% |
| FTSE 100 | 10,276.95 | 161.71 | -1.55% |
| HKSE | 26,364.35 | 261.93 | -0.98% |
| NASDAQ | 25,806.20 | 32.75 | -0.13% |
| Nikkei 225 | 62,480.59 | 353.25 | -0.56% |
| NZX 50 Index | 13,207.03 | 63.58 | -0.48% |
| S&P 500 | 7,337.11 | 28.01 | -0.38% |
| S&P/ASX 200 | 8,751.90 | 28.90 | -0.33% |
| SSE Composite Index | 4,169.08 | 11.02 | -0.26% |